WebDisclosure WebDisclosure
Basculer en Français
11085 Companies
243479 Keywords
171618 Articles
131121 Press releases
Headlines Articles Press releases Utility Therapeutics Ltd. Remove
  1. Home
  2. Companies
  3. Utility Therapeutics Ltd.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • PRESS RELEASE

    published on 01/17/2024 at 12:00, 2 years 8 months ago

    UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority Review

    UTILITY therapeutics Ltd. announces a private financing led by the AMR Action Fund and the U.S. FDA's acceptance of its New Drug Application (NDA) for PIVYA, a European-approved antibiotic for the treatment of uncomplicated urinary tract infections (UTIs). PIVYA has received the FDA's qualified infectious disease product (QIDP) designation, providing an additional 5 years of market exclusivity upon approval. This new antibiotic offers a unique mechanism of action and aims to address the rising rates of antimicrobial resistance. For more information, visit www.utilitytherapeutics.com.
    UTILITY Therapeutics PIVYA Urinary Tract Infections Antibiotic FDA Approval
    Logo of Utility Therapeutics Ltd.
Accesswire
  • Published on 09/28/2026 at 15:00, 2 hours 9 minutes ago

    Vox to Acquire Silver Royalty over the Sorby Hills Project in Australia

  • Published on 09/28/2026 at 14:45, 2 hours 24 minutes ago

    Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides

  • Published on 09/28/2026 at 14:30, 2 hours 39 minutes ago

    Drilling at Cat Creek Intersects a Copper-Molybdenum Porphyry System Visible Molybdenite-Chalcopyrite Over Significant Core Widths

  • Published on 09/28/2026 at 14:30, 2 hours 39 minutes ago

    Predictiv AI Completes United Nations Fleet Management Deployment Following Competitive Procurement Win

  • Published on 09/28/2026 at 14:00, 3 hours 9 minutes ago

    DoJ and DoW move to Support Resumption of Operations at Colosseum

View all ACCESSWIRE
EQS Group
  • Published on 09/28/2026 at 16:50, 19 minutes ago

    Tungsten San Juan initiates administrative procedure for the temporary suspension of mining activities

  • Published on 09/28/2026 at 16:05, 1 hour 4 minutes ago

    SwitchBot Launches RGBICWW Light Bars with Immersive Color, Everyday White Light, and Matter over Wi-Fi

  • Published on 09/28/2026 at 16:00, 1 hour 9 minutes ago

    EQS-Adhoc: Shelly Group SE: SE 2026 A SAS has registered voluntary public tender offer

  • Published on 09/28/2026 at 15:45, 1 hour 24 minutes ago

    Brooklyn Sports & Entertainment Names Alibaba Group an Official Technology and Cloud Partner of the Brooklyn Nets

  • Published on 09/28/2026 at 15:34, 1 hour 34 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.

View all EQS
Les Echos
  • Published on 09/28/2026 at 11:14, 5 hours 54 minutes ago

    260928 BENETEAU Transactions sur actions propres

  • Published on 09/28/2026 at 08:45, 8 hours 24 minutes ago

    BAIKOWSKI: 2026 first-half results

  • Published on 09/28/2026 at 08:45, 8 hours 24 minutes ago

    BAIKOWSKI : Résultats du 1er semestre 2026

  • Published on 09/28/2026 at 08:02, 9 hours 7 minutes ago

    Saint-Gobain signs renewable electricity purchase agreement in the United Kingdom

  • Published on 09/28/2026 at 08:02, 9 hours 7 minutes ago

    Saint-Gobain signe un contrat d’achat d’électricité renouvelable au Royaume-Uni

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy